Haemonetics Corporation, commonly referred to as Haemonetics, is a leading global healthcare company headquartered in the United States. Founded in 1971, the company has established itself as a key player in the blood management industry, focusing on innovative solutions for blood collection, processing, and transfusion. With major operational regions across North America, Europe, and Asia, Haemonetics serves hospitals and blood centres worldwide. The company’s core products include blood collection systems, automated blood processing equipment, and software solutions that enhance the efficiency and safety of blood management. Haemonetics is recognised for its commitment to quality and innovation, positioning itself as a trusted partner in the healthcare sector. Notable achievements include a strong market presence and a reputation for advancing transfusion medicine, making Haemonetics a vital contributor to improving patient outcomes globally.
How does Haemonetics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Haemonetics's score of 22 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Haemonetics Corporation reported total carbon emissions of approximately 25,778,620 kg CO2e, comprising 5,701,850 kg CO2e from Scope 1 and 19,361,770 kg CO2e from Scope 2 emissions. This data reflects a commitment to transparency in their environmental impact, with emissions figures disclosed for both Scope 1 and Scope 2, while Scope 3 emissions data remains undisclosed. Comparatively, in 2021, the company recorded total emissions of about 26,822,440 kg CO2e, with Scope 1 emissions at 5,071,360 kg CO2e and Scope 2 emissions at 21,180,860 kg CO2e. This indicates a slight reduction in total emissions from 2021 to 2022. Haemonetics has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, which suggests a need for further commitment in this area. The absence of documented reduction targets highlights an opportunity for the company to enhance its climate strategy and align with industry standards for sustainability. Overall, while Haemonetics has made strides in reporting its emissions, the lack of ambitious reduction commitments may limit its effectiveness in addressing climate change.
Access structured emissions data, company-specific emission factors, and source documents
2020 | 2021 | 2022 | |
---|---|---|---|
Scope 1 | 5,168,600 | 0,000,000 | 0,000,000 |
Scope 2 | 22,983,160 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Haemonetics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.